P. R. Harrigan

发表

Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir

J. Joy, A. Poon, C. Chui, 2015, Journal of Clinical Microbiology.

NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain

C. G. Fedele, A. Alvaro-Meca, V. Briz, 2016, PloS one.

Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients.

P. Cullis, K. Wong, T. Redelmeier, 1993, Biochimica et biophysica acta.

Protection of liposomes during dehydration or freezing.

P. Cullis, T. D. Madden, P. Harrigan, 1990, Chemistry and physics of lipids.

Clinical utility of testing human immunodeficiency virus for drug resistance.

P. Harrigan, H. Côté, British Columbia., 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient

K. Savage, E. Yoshida, P. Harrigan, 2006, American journal of hematology.

Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates

B. Larder, M. D. Miller, P. Harrigan, 2002, Antimicrobial Agents and Chemotherapy.

Implementation of Next-Generation Sequencing for Hepatitis B Virus Resistance Testing and Genotyping in a Clinical Microbiology Laboratory

T. Mazzulli, P. Harrigan, C. Sherlock, 2015, Journal of Clinical Microbiology.

Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency

B. Wynhoven, A. Poon, N. Sluis-Cremer, 2008, AIDS.

N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance

B. Wynhoven, Mark Zanin, N. Sluis-Cremer, 2007, PLoS medicine.

An activator of G protein-coupled receptor and MEK1/2-ERK1/2 signaling inhibits HIV-1 replication by altering viral RNA processing

B. Blencowe, Q. Pan, P. Stoilov, 2020, PLoS pathogens.

Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation

B. Blencowe, P. Stoilov, P. Harrigan, 2017, Retrovirology.

Modulation of the splicing regulatory function of SRSF10 by a novel compound that impairs HIV-1 replication

M. Blanchette, L. Shkreta, Johanne Toutant, 2016, Nucleic acids research.

A Parallel Synthesis Approach to the Identification of Novel Diheteroarylamide-Based Compounds Blocking HIV Replication: Potential Inhibitors of HIV-1 Pre-mRNA Alternative Splicing.

B. Chabot, P. Harrigan, P. Cheung, 2016, Journal of medicinal chemistry.

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

P. Harrigan, B. Yip, R. Hogg, 2005, The Journal of infectious diseases.

Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy

K. Hertogs, W. Verbiest, B. Larder, 2002, Antiviral therapy.

Compounds producing an effective combinatorial regimen for disruption of HIV‐1 latency

I. Sadowski, T. Pfeifer, Pargol Hashemi, 2017, EMBO molecular medicine.

Selection and Characterization of HIV-1 Variants Resistant to the (+) and (-) Enantiomers of 2′-Deoxy-3′-Oxa-4′-Thiocytidine (Dotc)

M. Wainberg, H. Salomón, J. Bédard, 1998, Antiviral therapy.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation

Philip L. Tzou, D. Katzenstein, R. Shafer, 2017, PloS one.

Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial

J. Singer, B. Angus, D. Ayers, 2010, Journal of acquired immune deficiency syndromes.

Lopinavir/Ritonavir Pharmacokinetics in a Substitution of High‐Dose Soft‐Gelatin Capsule to Tablet Formulation

J. Montaner, M. Harris, M. Hull, 2009, Journal of clinical pharmacology.

E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.

Michael I. Jordan, J. Mellors, N. Parkin, 2014, Antiviral research.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa

J. Mellors, C. Brumme, C. Wallis, 2018, Antiviral chemistry & chemotherapy.

The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey.

M. Bally, L. Mayer, P. Cullis, 1990, Chemistry and physics of lipids.

Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFκB

I. Sadowski, V. Simon, C. Brumme, 2014, Retrovirology.

Extreme Responses to Climate Change in Antarctic Lakes

L. Peck, J. Ellis-Evans, W. Quayle, 2002, Science.

Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS

A. Levy, R. Hogg, J. Montaner, 2005, Lipids in Health and Disease.

Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations

N. Sluis-Cremer, P. Harrigan, M. Tachedjian, 2015, Nucleic acids research.

Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes

Rosemary M. McCloskey, Jaclyn K. Mann, B. Walker, 2013, Retrovirology.

The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus

J. Joy, P. Harrigan, A. Howe, 2018, Virus evolution.

Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance.

Paul Sandstrom, Roger Paredes, Marc Noguera-Julian, 2017, The Journal of infectious diseases.

Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV

D. Kuritzkes, J. Schapiro, P. Cahn, 2022, HIV medicine.

GWATCH: a web platform for automated gene association discovery analysis

S. O’Brien, M. V. Van Natta, D. Jabs, 2014, GigaScience.

Selection of drug-resistant HIV.

C. Alexander, P. R. Harrigan, 1999, Trends in microbiology.

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

F. Ceccherini‐Silberstein, J. Pawlotsky, J. Lennerstrand, 2021, Viruses.

HCV Genotype-1 Subtypes and Resistance-Associated Substitutions in Drug-Naive and in Direct-Acting Antiviral Treatment Failure Patients

Ofer Peleg, O. Mor, E. Mendelson, 2017, Antiviral therapy.

HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.

P. Harrigan, J. Montaner, B. Wynhoven, 2005, The Journal of infectious diseases.

Determination of transmembrane pH gradients and membrane potentials in liposomes.

P. Cullis, M. Hope, T. Redelmeier, 1992, Biophysical journal.

Increased Prevalence of Controlled Viremia and Decreased Rates of HIV Drug Resistance Among HIV-Positive People Who Use Illicit Drugs During a Community-wide Treatment-as-Prevention Initiative.

J. Montaner, E. Wood, T. Kerr, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy.

L. Bacheler, P. Harrigan, Z. Brumme, 2007, AIDS research and human retroviruses.

HIV-1 Genetic Diversity in Antenatal Cohort, Canada

B. Brenner, N. Lapointe, P. Harrigan, 2005, Emerging infectious diseases.

Influence of ion gradients on the transbilayer distribution of dibucaine in large unilamellar vesicles.

L. Mayer, P. Cullis, K. Wong, 1988, Biochemistry.

Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury

D. Dorscheid, P. Harrigan, Z. Brumme, 2003, Critical care.

A Mutation in the 3′ Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance

D. Stammers, B. Larder, S. Kemp, 2002, Journal of Virology.

Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients.

M. Bally, L. Mayer, P. Cullis, 1988, Chemistry and physics of lipids.

Technical and Regulatory Shortcomings of the TaqMan Version 1 HIV Viral Load Assay

B. Yip, J. Montaner, B. Wynhoven, 2012, PloS one.

Viral load testing in a resource-limited setting: quality control is critical

P. Harrigan, P. Cros, P Richard Harrigan, 2011, Journal of the International AIDS Society.

Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings

J. Montaner, P. Harrigan, M. Hull, 2016, Journal of the International AIDS Society.

An assessment of Nano-RECall: Interpretation of Oxford Nanopore sequence data for HIV-1 drug resistance testing

P. Harrigan, U. Parikh, C. Woods, 2022, bioRxiv.

Uptake of basic amino acids and peptides into liposomes in response to transmembrane pH gradients.

P. Cullis, P. Harrigan, I. Clark‐Lewis, 1992, Biophysical journal.

Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years

J. Singer, J. Montaner, Zunyou Wu, 2014, Journal of the International AIDS Society.

Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors

L. Bacheler, B. Wynhoven, P. Harrigan, 2005, AIDS.

Identification of small molecule modulators of HIV-1 Tat and Rev protein accumulation

B. Blencowe, P. Stoilov, P. Cheung, 2017, Retrovirology.